Browsing by Author "McLeod, Howard L."

Now showing 1 - 7 of 7
  • Thumbnail Image
    Item
    Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
    (Springer Nature, 2022) Quintanilha, Julia C.F.; Wang, Jin; Sibley, Alexander B.; Jiang, Chen; Etheridge, Amy S.; Shen, Fei; Jiang, Guanglong; Mulkey, Flora; Patel, Jai N.; Hertz, Daniel L.; Dees, Elizabeth Claire; McLeod, Howard L.; Bertagnolli, Monica; Rugo, Hope; Kindler, Hedy L.; Kelly, William Kevin; Ratain, Mark J.; Kroetz, Deanna L.; Owzar, Kouros; Schneider, Bryan P.; Lin, Danyu; Innocenti, Federico; Medicine, School of Medicine
    Background: Hypertension and proteinuria are common bevacizumab-induced toxicities. No validated biomarkers are available for identifying patients at risk of these toxicities. Methods: A genome-wide association study (GWAS) meta-analysis was performed in 1039 bevacizumab-treated patients of European ancestry in four clinical trials (CALGB 40502, 40503, 80303, 90401). Grade ≥2 hypertension and proteinuria were recorded (CTCAE v.3.0). Single-nucleotide polymorphism (SNP)-toxicity associations were determined using a cause-specific Cox model adjusting for age and sex. Results: The most significant SNP associated with hypertension with concordant effect in three out of the four studies (p-value <0.05 for each study) was rs6770663 (A > G) in KCNAB1, with the G allele increasing the risk of hypertension (p-value = 4.16 × 10-6). The effect of the G allele was replicated in ECOG-ACRIN E5103 in 582 patients (p-value = 0.005). The meta-analysis of all five studies for rs6770663 led to p-value = 7.73 × 10-8, close to genome-wide significance. The most significant SNP associated with proteinuria was rs339947 (C > A, between DNAH5 and TRIO), with the A allele increasing the risk of proteinuria (p-value = 1.58 × 10-7). Conclusions: The results from the largest study of bevacizumab toxicity provide new markers of drug safety for further evaluations. SNP in KCNAB1 validated in an independent dataset provides evidence toward its clinical applicability to predict bevacizumab-induced hypertension.
  • Thumbnail Image
    Item
    Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation
    (Oxford University Press, 2010-10-13) Freedman, Andrew N.; Sansbury, Leah B.; Figg, William D.; Potosky, Arnold L.; Smith, Sheila R. Weiss; Khoury, Muin J.; Nelson, Stefanie A.; Weinshilboum, Richard M.; Ratain, Mark J.; McLeod, Howard L.; Epstein, Robert S.; Ginsburg, Geoffrey S.; Schilsky, Richard L.; Liu, Geoffrey; Flockhart, David A.; Ulrich, Cornelia M.; Davis, Robert L.; Lesko, Lawrence J.; Zineh, Issam; Randhawa, Gurvaneet; Ambrosone, Christine B.; Relling, Mary V.; Rothman, Nat; Xie, Heng; Spitz, Margaret R.; Ballard-Barbash, Rachel; Doroshow, James H.; Minasian, Lori M.; Medicine, School of Medicine
    Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled “Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation” on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructure-based recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen- and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.
  • Thumbnail Image
    Item
    Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
    (Springer Nature, 2022) Quintanilha, Julia C.F.; Wang, Jin; Sibley, Alexander B.; Jiang, Chen; Etheridge, Amy S.; Shen, Fei; Jiang, Guanglong; Mulkey, Flora; Patel, Jai N.; Hertz, Daniel L.; Dees, Elizabeth Claire; McLeod, Howard L.; Bertagnolli, Monica; Rugo, Hope; Kindler, Hedy L.; Kelly, William Kevin; Ratain, Mark J.; Kroetz, Deanna L.; Owzar, Kouros; Schneider, Bryan P.; Lin, Danyu; Innocenti, Federico; Medicine, School of Medicine
    Correction to: British Journal of Cancer 10.1038/s41416-021-01557-w, published online 06 October 2021 The original version of this article unfortunately contained a mistake in an author affiliation. Dr. Kouros Owzar was listed as “Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA”, when it should be “Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA”. The original article has been corrected.
  • Thumbnail Image
    Item
    Genome-Wide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy
    (Wiley, 2020-09) Chua, Katherina C.; Xiong, Chenling; Ho, Carol; Mushiroda, Taisei; Jiang, Chen; Mulkey, Flora; Lai, Dongbing; Schneider, Bryan P.; Rashkin, Sara R.; Witte, John S.; Friedman, Paula N.; Ratain, Mark J.; McLeod, Howard L.; Rugo, Hope S.; Shulman, Lawrence N.; Kubo, Michiaki; Owzar, Kouros; Kroetz, Deanna L.; Medical and Molecular Genetics, School of Medicine
    Microtubule targeting agents (MTAs) are anticancer therapies commonly prescribed for breast cancer and other solid tumors. Sensory peripheral neuropathy (PN) is the major dose-limiting toxicity for MTAs and can limit clinical efficacy. The current pharmacogenomic study aimed to identify genetic variations that explain patient susceptibility and drive mechanisms underlying development of MTA-induced PN. A meta-analysis of genome-wide association studies (GWAS) from two clinical cohorts treated with MTAs (CALGB 40502 and CALGB 40101) was conducted using a Cox regression model with cumulative dose to first instance of grade 2 or higher PN. Summary statistics from a GWAS of European subjects (n = 469) in CALGB 40502 that estimated cause-specific risk of PN were meta-analyzed with those from a previously published GWAS of European ancestry (n = 855) from CALGB 40101 that estimated the risk of PN. Novel single nucleotide polymorphisms in an enhancer region downstream of sphingosine-1-phosphate receptor 1 (S1PR1 encoding S1PR1; e.g., rs74497159, βCALGB 40101 per allele log hazard ratio (95% CI) = 0.591 (0.254 – 0.928), βCALGB 40502 per allele log hazard ratio (95% CI) = 0.693 (0.334 – 1.053); PMETA = 3.62×10−7) were the most highly ranked associations based on P-values with risk of developing grade 2 and higher PN. In silico functional analysis identified multiple regulatory elements and potential enhancer activity for S1PR1 within this genomic region. Inhibition of S1PR1 function in iPSC-derived human sensory neurons shows partial protection against paclitaxel-induced neurite damage. These pharmacogenetic findings further support ongoing clinical evaluations to target S1PR1 as a therapeutic strategy for prevention and/or treatment of MTA-induced neuropathy.
  • Thumbnail Image
    Item
    Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated With Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
    (American Association for Cancer Research, 2019-10-01) Li, Megan; Mulkey, Flora; Jiang, Chen; O’Neil, Bert H.; Schneider, Bryan P.; Shen, Fei; Friedman, Paula N.; Momozawa, Yukihide; Kubo, Michiaki; Niedzwiecki, Donna; Hochster, Howard S.; Lenz, Heinz-Josef; Atkins, James N.; Rugo, Hope S.; Halabi, Susan; Kelly, William Kevin; McLeod, Howard L.; Innocenti, Federico; Ratain, Mark J.; Venook, Alan P.; Owzar, Kouros; Kroetz, Deanna L.; Medicine, School of Medicine
    Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of multiple cancers. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy or lead to cardiovascular complications. The factors that contribute to interindividual variability in blood pressure rise during bevacizumab treatment are not well understood.Experimental Design: To identify genomic regions associated with bevacizumab-induced hypertension risk, sequencing of candidate genes and flanking regulatory regions was performed on 61 patients treated with bevacizumab (19 cases developed early-onset grade 3 hypertension and 42 controls had no reported hypertension in the first six cycles of treatment). SNP-based tests for common variant associations and gene-based tests for rare variant associations were performed in 174 candidate genes.Results: Four common variants in independent linkage disequilibrium blocks between SLC29A1 and HSP90AB1 were among the top associations. Validation in larger bevacizumab-treated cohorts supported association between rs9381299 with early grade 3+ hypertension (P = 0.01; OR, 2.4) and systolic blood pressure >180 mm Hg (P = 0.02; OR, 2.1). rs834576 was associated with early grade 3+ hypertension in CALGB 40502 (P = 0.03; OR, 2.9). These SNP regions are enriched for regulatory elements that may potentially increase gene expression. In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension.
  • Thumbnail Image
    Item
    Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
    (Wiley, 2016-02) Kalman, Lisa V.; Agúndez, José A.G.; Appell, Malin Lindqvist; Bell, Gillian C.; Boukouvala, Sotiria; Bruckner, Carsten; Bruford, Elspeth; Bruckner, Carsten; Caudle, Kelly; Coulthard, Sally; Daly, Ann K.; Del Tredici, Johan T.; Drozda, Katarzyna; Everts, Robin; Flockhart, David; Freimuth, Robert; Gaedigk, Andrea; Hachad, Houda; Hartshorne, Toinette; Ingelman-Sundberg, Magnus; Klein, Teri E.; Lauschke, Volker M.; Maglott, Donna R.; McLeod, Howard L.; McMillin, Gwendolyn A.; Meyer, Urs A.; Müller, Daniel J.; Nickerson, Deborah A.; Oetting, William S.; Pacanowski, Michael; Pratt, Victoria M.; Relling, Mary V.; Roberts, Ali; Rubinstein, Wendy S.; Sangkuhl, Katrin; Schwab, Matthias; Scott, Stuart A.; Sim, Sarah C.; Thirumaran, Ranjit K.; Toji, Lorraine H.; Tyndale, Rachel; van Schaik, Ron HN; Whirl-Carrillo, Michelle; Yeo, Kiang-Teck J.; Zanger, Ulrich M.; Department of Medical & Molecular Genetics, IU School of Medicine
    This manuscript provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward.
  • Thumbnail Image
    Item
    Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
    (Wiley, 2018-05) Volpi, Simona; Bult, Carol J.; Chisholm, Rex L.; Deverka, Patricia A.; Ginsburg, Geoffrey S.; Jacob, Howard J.; Kasapi, Melpomeni; McLeod, Howard L.; Roden, Dan M.; Williams, Marc S.; Green, Eric D.; Rodriguez, Laura Lyman; Aronson, Samuel; Cavallari, Larisa H.; Denny, Joshua C.; Dressler, Lynn G.; Johnson, Julie A.; Klein, Teri E.; Leeder, J. Steven; Piquette-Miller, Micheline; Perera, Minoli; Rasmussen-Torvik, Laura J.; Rehm, Heidi L.; Ritchie, Marylyn D.; Skaar, Todd C.; Wagle, Nikhil; Weinshilboum, Richard; Weitzel, Kristin W.; Wildin, Robert; Wilson, John; Manolio, Teri A.; Relling, Mary V.; Pharmacology and Toxicology, School of Medicine
    Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.